Long Position on HROW @ $18.10 on 3/17/2023 (Momentum)

Harrow Health, Inc. (HROW) operates as an ophthalmic-focused healthcare company. 

The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation.

The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.

Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. 

Shares have formed a bullish "wedge" that is supported by the stock's 50-day moving average. Higher share prices are expected.

Entrry Point: $18.10

Stop Loss: $17.10

Trading Range: $5.40 to $20.30

Target Price: $19.90

Position closed on 3/23/2023 at price of $17.10 with a -5.52% loss in 6 days.

Back to Portfolio